The combined company will trade under the name Tevogen Holdings, the transaction expected to be completed in the fourth quarter of 2023. Image credit: Shutterstock/kan_khampanya

There could soon be a TVGN ticker on the New York Stock Exchange (NYSE), after Tevogen Bio revealed plans of a billion-dollar deal to combine with special purpose acquisition company (SPAC) Semper Paratus Acquisition Corporation.

The New Jersey, US-based biotech company expects the value of the merger to be approximately $1.2bn and the combined company will trade under the name Tevogen Holdings. The transaction is pegged to be completed in the fourth quarter of 2023.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Tevogen Bio currently has a pipeline investigating T cell therapy. Its proprietary technology platform – ExacTcell – uses CD8+ cytotoxic T lymphocytes (CTLs) and uses the body’s native T cell receptor pool to provide enhanced safety.

In January 2023, the company reported positive data from its lead candidate TVGN 489 for the treatment of Covid-19 in high-risk patients. In the statement announcing public listing intention, Tevogen Bio said it will target therapies for non-viral-induced common cancers and multiple sclerosis upon completion of the transaction.

The transaction will also help the company pursue several late-stage trials and expand its manufacturing capacity.

See Also:

The biotech industry has been in a lull of initial public offerings, and 2023 has seen fundraising difficulties amidst rising inflation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Tevogen Bio’s goal is to provide access to the vast and unprecedented potential of personalised immunotherapies for large patient populations impacted by common cancers and viral infections,” Tevogen Bio’s founder and CEO, Dr Ryan Saadi said.

“Tevogen Bio’s rapid growth from concept to a fully operational biotech company in less than 24 months is the result of ambitious goals and well-executed strategies by its highly motivated and skilled team of experts,” said Semper Paratus ‘s CEO Suren Ajjarapu.

Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.